ArriVent Plans to Present Initial Phase 1 Data at ESMO 2026
ArriVent BioPharma announced it will present initial safety and efficacy data for its CDH17-targeted ADC ARR-217 in patients with gastrointestinal cancers at the ESMO Congress 2026.
Related stories
Microsoft Restores Services After Global Outage
Microsoft said services had fully recovered across Teams, Outlook, Copilot and other applications, ending an outage that disrupted online communications for businesses and governme
M impact | EQUITY | Nov 14, 2026, 06:49 AM UTC
Microsoft Says All Services Restored After Global Outage
Microsoft said all services were restored after a global outage.
M impact | EQUITY | Nov 14, 2026, 06:49 AM UTC
Microsoft says outage issue addressed and remaining service restored
Microsoft says it completed efforts to address the underlying issue and restored service to remaining impacted customers and regions.
M impact | EQUITY | Nov 14, 2026, 06:37 AM UTC
Microsoft Completes Outage Fix, Restores Service to Remaining Customers
Microsoft says it completed efforts to address the underlying issue and restored service to remaining impacted customers and regions.
L impact | EQUITY | Nov 14, 2026, 06:37 AM UTC
Microsoft Says Consumer Services Recovered, Enterprise Recovery Ongoing
Microsoft said its consumer products services had fully recovered at 4:10 p.m. UTC Friday, while Microsoft 365 enterprise services were seeing some sustained recovery. The company
M impact | EQUITY | Nov 14, 2026, 05:32 AM UTC
Microsoft Says Consumer Products Services Recovered
Microsoft said its consumer products services had fully recovered, while Microsoft 365 enterprise services were seeing a sustained recovery.
M impact | EQUITY | Nov 14, 2026, 05:17 AM UTC